Holen Sie sich die Stockscreener-App
362.43
0.36%
-1.30
Handel nachbörslich:
362.43
Schlusskurs vom Vortag:
$363.73
Offen:
$367.86
24-Stunden-Volumen:
297.39K
Relative Volume:
1.37
Marktkapitalisierung:
$9.69B
Einnahmen:
$2.59B
Nettoeinkommen (Verlust:
$168.80M
KGV:
59.66
EPS:
6.0748
Netto-Cashflow:
$357.20M
1W Leistung:
-1.49%
1M Leistung:
-1.66%
6M Leistung:
+24.02%
1J Leistung:
+18.81%
1-Tages-Spanne:
$361.26
$371.07
1-Wochen-Bereich:
$353.97
$372.59
52-Wochen-Spanne:
$236.73
$396.23
Bio Rad Laboratories Inc Stock (BIO) Company Profile
Firmenname
Bio Rad Laboratories Inc
Sektor
Branche
Telefon
(510) 724-7000
Adresse
1000 ALFRED NOBEL DRIVE, HERCULES
Compare BIO vs ABT, MDT, SYK, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BIO
Bio Rad Laboratories Inc
|
362.43 | 9.69B | 2.59B | 168.80M | 357.20M | 6.0748 |
ABT
Abbott Laboratories
|
102.97 | 178.18B | 46.59B | 5.41B | 7.38B | 3.0938 |
MDT
Medtronic Plc
|
94.23 | 120.53B | 36.36B | 4.84B | 5.43B | 3.7261 |
SYK
Stryker Corp
|
281.62 | 108.02B | 25.27B | 3.34B | 4.57B | 8.6334 |
BSX
Boston Scientific Corp
|
43.00 | 62.32B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
86.45 | 49.83B | 6.30B | 1.07B | 1.09B | 1.8406 |
Bio Rad Laboratories Inc Stock (BIO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-05-15 | Fortgesetzt | RBC Capital Mkts | Outperform |
| 2026-04-07 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-10-01 | Hochstufung | Citigroup | Neutral → Buy |
| 2024-08-28 | Eingeleitet | Wells Fargo | Equal Weight |
| 2024-06-03 | Fortgesetzt | Jefferies | Hold |
| 2024-04-03 | Herabstufung | Citigroup | Buy → Neutral |
| 2023-12-07 | Eingeleitet | UBS | Buy |
| 2023-06-16 | Eingeleitet | Wells Fargo | Overweight |
| 2022-12-07 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2022-08-25 | Eingeleitet | Credit Suisse | Outperform |
| 2022-01-28 | Bestätigt | Citigroup | Buy |
| 2020-01-08 | Eingeleitet | Wells Fargo | Overweight |
| 2020-01-07 | Eingeleitet | Citigroup | Buy |
| 2018-10-17 | Eingeleitet | Goldman | Buy |
| 2018-09-20 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2018-02-16 | Herabstufung | CL King | Buy → Neutral |
| 2017-07-13 | Eingeleitet | Wells Fargo | Outperform |
| 2017-06-28 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2017-01-18 | Eingeleitet | Deutsche Bank | Hold |
| 2016-10-13 | Eingeleitet | CL King | Buy |
| 2015-05-06 | Bestätigt | Jefferies | Buy |
| 2009-12-18 | Eingeleitet | Maxim Group | Buy |
| 2009-11-06 | Eingeleitet | Jefferies & Co | Buy |
| 2009-07-17 | Eingeleitet | Soleil | Buy |
| 2007-09-26 | Eingeleitet | Banc of America Sec | Buy |
| 2007-02-23 | Herabstufung | Robert W. Baird | Outperform → Neutral |
Alle ansehen
Bio Rad Laboratories Inc Aktie (BIO) Neueste Nachrichten
Neogen (NEOG) Q1 Earnings and Revenues Beat Estimates - Zacks Investment Research
Global Microfluidics Market by Product Type, Application, End User, and Region, 2026-2036 | $48.04 Billion Opportunity Driven by Point-of-Care Diagnostics and Automation - GlobeNewswire Inc.
Bio-Rad Reports Second-Quarter 2026 Financial Results - Investing News Network
Europe Point of Care Diagnostics Market Size and Forecast, 20212031 | Market to Reach US$21.4 Billion by 2031 as Rapid Testing and Molecular Innovation Drive 13.4% CAGR - GlobeNewswire Inc.
Immunogenomics Market Size, Share, Trends, and Growth Forecast, 2026-2033 | NGS and Personalized Medicine Drive Market Toward USD 9.82 Billion at 5.97% CAGR - GlobeNewswire Inc.
Magnetic Beads MarketGlobal Forecast and Growth Opportunities, 2026-2032 | Automation, Genomics, and Molecular Diagnostics Drive 7.91% CAGR Toward USD 6.18 Billion - GlobeNewswire Inc.
North America Non-Viral Transfection Reagents Market Forecast to 2035 | Cell and Gene Therapy Demand Drives 8.5% CAGR and a USD 0.70 Billion Opportunity - GlobeNewswire Inc.
Bio-Rad Laboratories, Inc. Class A Revenue Breakdown – HAN:BUWA - tradingview.com
Bio-Rad Laboratories Inc Stock Intrinsic Values | HAM:BUWA - gurufocus.com
Bio-Rad Laboratories Inc Stock Baskets - gurufocus.com
Veterinary Diagnostics Market Size to Soar to USD 30.78 Billion by 2035 at a CAGR of 10.1%SNS Insider - GlobeNewswire Inc.
Global Therapeutic Drug Monitoring Consumables Market Forecast, 2026-2032AI-Enabled Automation and Integrated Lab Workflows Drive 8.22% CAGR, Lifting the Market to USD 586.85 Million by 2032 - GlobeNewswire Inc.
Weekly Recap: Bio-Rad growth and margin plan and digital PCR expansion - TradingView
Bio-Rad Laboratories, Inc. (BIO-B) Stock Price, News, Quote & History - Yahoo! Finance Canada
Here's Why You Should Hold Bio-Rad Stock in Your Portfolio for Now - Zacks Investment Research
Global Metabolomics Market to Reach US$9.01 Billion by 2035 as Precision Medicine, Biomarker Discovery and Advanced Analytics Unlock New Opportunities - GlobeNewswire Inc.
Magnetic Bead Purification Kits Market Outlook 2026-2030: Investment Trends, Strategic Profiles and Revenue Share Outlook - GlobeNewswire Inc.
Bio-Rad to Participate in Fireside Chat During Bernstein Insights Healthcare Leaders and Disruptors 3rd Annual Forum - Investing News Network
Bio-Rad Laboratories, Inc. at Wells Fargo Healthcare Conference Transcript - GuruFocus
BIO-RAD LABORATORIES (NYSE: BIO) Grants 719 Derivative Securities to Director Allison Schwartz - Kalkine Media
BIO-RAD LABORATORIES Executive Evran Sedat Reports Exercising 3,880 Shares (NYSE: BIO) - Kalkine Media
Bio-Rad: Favorable Read-Across From Investor Event (NYSE:BIO) - Seeking Alpha
Bio-Rad (NYSE: BIO) director sees 320 RSUs convert, 116 shares withheld - Stock Titan
Bio-Rad (NYSE: BIO) EVP logs 4,313 RSU grant and 2,179 vested shares - Stock Titan
[Form 4] BIO-RAD LABORATORIES, INC. Insider Trading Activity - Stock Titan
1,453 stock units vest for Bio-Rad (NYSE: BIO) insider as 551 shares withheld - Stock Titan
Bio-Rad (NYSE: BIO) grants EVP 4,601 RSUs, with shares withheld at $386.11 - Stock Titan
[Form 4] BIO-RAD LABORATORIES, INC. Insider Trading Activity - Stock Titan
Bio-Rad at Wells Fargo conference: margin push takes center stage - Investing.com Canada
Bio-Rad at Wells Fargo conference: margin push takes center stage - Investing.com India
Bio-Rad at Wells Fargo conference: margin push takes center stage - Investing.com UK
Bio-Rad Terminates Forbes Tate Lobbying Pact - Legis1
Behavioral Patterns of BIO and Institutional Flows - Stock Traders Daily
Bio-Rad expands range of Foresight prepacked chromatography columns for biomanufacturing - selectscience.net
Chromatography Reagents Market 2026-2030 | Global key Player; - openPR.com
Bio-Rad Laboratories, Inc. (BIO) Stock Analysis: Navigating Current Market Challenges with Strategic Insights - DirectorsTalk Interviews
Bio-Rad's Timing for Revenue Growth Recovery Remains Uncertain - Morningstar
Mesa Laboratories Inc. (MLAB) Peer Comparison – Compare with Others - valueresearchonline.com
BIO-RAD (NYSE: BIO) Director Allison Schwartz Reports 1,573 Shares Following Option Exercise - Kalkine Media
Global Multiplex Assays Market 2026 Edition Consumables Dominate Multiplex Assays with 68% Market Share - GlobeNewswire Inc.
Bio-Rad Laboratories Inc. Class A (BIO) Key Financial Ratios – Valuation, Profitability & More - Value Research
RSU vesting gives Bio-Rad (NYSE: BIO) exec 425 shares - Stock Titan
[Form 4] BIO-RAD LABORATORIES, INC. Insider Trading Activity - Stock Titan
Bio-Rad (BIO) Up 11.7% Since Last Earnings Report: Can It Continue? - finance.yahoo.com
Bio-Rad expands Foresight Pro prepacked chromatography columns with Nuvia ion exchange and mixed-mode resins - manufacturingchemist.com
Allied Healthcare Products Inc. (AHPI) Peer Comparison – Compare with Others - Value Research
Best Practices for qPCR Assay Design and Optimization - the-scientist.com
Bio-Rad expands Foresight Pro Prepacked Chromatography Columns with Nuvia Ion Exchange and Mixed-Mode Resins for Biomanufacturing - Cambridge Network
Bio-Rad to Participate in Fireside Chat During Wells Fargo's 21st Annual Healthcare Conference - Investing News Network
Bio-Rad to Participate in Fireside Chat During Wells Fargo’s 21st Annual Healthcare Conference - Yahoo Finance
Finanzdaten der Bio Rad Laboratories Inc-Aktie (BIO)
Umsatz
Nettogewinn
Free Cashflow
ENV
Bio Rad Laboratories Inc-Aktie (BIO) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| EVRAN SEDAT | EVP, Global Supply Chain |
Sep 06 '26 |
Option Exercise |
0.00 |
864 |
0 |
3,880 |
| ENGELHARDT EVA ANETTE | EVP, President, CDG |
Sep 06 '26 |
Option Exercise |
0.00 |
1,152 |
0 |
2,313 |
| Lakkaraju Roop Kalyan | EVP, Chief Financial Officer |
Sep 06 '26 |
Option Exercise |
0.00 |
1,536 |
0 |
4,933 |
| ENLOE COURTNEY C | EVP, General Counsel & Sec |
Sep 06 '26 |
Option Exercise |
0.00 |
768 |
0 |
1,957 |
| SCHWARTZ NORMAN D | Chairman & CEO |
Sep 06 '26 |
Option Exercise |
0.00 |
3,455 |
0 |
450,873 |
| BARRY JAMES | EVP, President, LSG |
Sep 06 '26 |
Option Exercise |
0.00 |
1,056 |
0 |
2,495 |
| ENLOE COURTNEY C | EVP, General Counsel & Sec |
Sep 05 '26 |
Option Exercise |
0.00 |
685 |
0 |
1,435 |
| Mehta Rajat | EVP, GBL Commercial Operations |
Sep 05 '26 |
Option Exercise |
0.00 |
1,826 |
0 |
1,736 |
| Lakkaraju Roop Kalyan | EVP, Chief Financial Officer |
Sep 05 '26 |
Option Exercise |
0.00 |
1,370 |
0 |
3,956 |
| SCHWARTZ NORMAN D | Chairman & CEO |
Sep 05 '26 |
Option Exercise |
0.00 |
4,109 |
0 |
450,294 |
8.33%
3.04%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):